[ Thu, Jan 23rd 2025 ]: WOPRAI
As of Jan 23rd, 2025, there has been substantial selling of Locafy Limited in recent trading
[ Thu, Jan 23rd 2025 ]: WOPRAI
As of Jan 23rd, 2025, there has been substantial selling of in recent trading
[ Thu, Jan 23rd 2025 ]: MSN
[ Thu, Jan 23rd 2025 ]: WOPRAI
[ Thu, Jan 23rd 2025 ]: cnbctv18
Ansid Capital recommends private banks, cautions on IT valuations
[ Wed, Jan 22nd 2025 ]: Moneyweb
To save or invest: Understanding the difference between stokvels and investing
[ Wed, Jan 22nd 2025 ]: Indiatimes
[ Wed, Jan 22nd 2025 ]: MSN
Want Almost $14,000 per Year in Dependable Passive Income? Invest $25,000 in These 4 Stocks
[ Wed, Jan 22nd 2025 ]: MSN
Want Decades of Passive Income? 4 Stocks to Buy Now and Hold Forever
[ Wed, Jan 22nd 2025 ]: Kiplinger
Stock Market Today: Earnings and AI Send Stocks to New Highs
[ Wed, Jan 22nd 2025 ]: MSN
Why Is Banco Santander, S.A. (SAN) Among the Best Large-Cap Value Stocks to Buy in 2025?
[ Wed, Jan 22nd 2025 ]: MSN
Why Is The Cigna Group (CI) Among the Best Large-Cap Value Stocks to Buy in 2025?
[ Wed, Jan 22nd 2025 ]: MSN
[ Wed, Jan 22nd 2025 ]: MSN
[ Wed, Jan 22nd 2025 ]: bnnbloomberg
S&P 500 Hits Record High as AI Powers Tech Rally: Markets Wrap
[ Wed, Jan 22nd 2025 ]: MSN
Why PBF Energy Inc. (PBF) Is One of the Worst Performing Energy Stocks in 2024?
[ Wed, Jan 22nd 2025 ]: MSN
Is Wynn Resorts (WYNN) the Best Sin Stock to Invest in 2025?
[ Wed, Jan 22nd 2025 ]: MSN
Is Churchill Downs Incorporated (CHDN) the Best Sin Stock to Invest in 2025?
[ Wed, Jan 22nd 2025 ]: AOL
Apple vs. Tesla: Which Tech Giant Will Be the Better Investment in 2025?
[ Wed, Jan 22nd 2025 ]: MSN
[ Wed, Jan 22nd 2025 ]: Kiplinger
[ Wed, Jan 22nd 2025 ]: MSN
3 High-Yield Dividend ETFs to Buy to Generate Passive Income
[ Wed, Jan 22nd 2025 ]: Kiplinger
[ Wed, Jan 22nd 2025 ]: MSN
[ Wed, Jan 22nd 2025 ]: bnnbloomberg
Trade War Threatens Canadian Banks Stocks' Rally After 27% Surge
[ Wed, Jan 22nd 2025 ]: Kiplinger
Exelixis's SWOT analysis: cabozantinib growth and zanzalintinib potential buoy stock
Exelixis, Inc. (NASDAQ:EXEL), currently trading near $33, continues to build on the success of its flagship product cabozantinib while advancing a promising pipeline led by zanzalintinib. According to InvestingPro data,

Read the Full MSN Article at:
https://www.msn.com/en-us/money/top-stocks/exelixis-s-swot-analysis-cabozantinib-growth-and-zanzalintinib-potential-buoy-stock/ar-AA1xGLXa
[ Thu, Jan 09th 2025 ]: MSN
SoundHound AI Stock Rose Over 800% in 2024. Is It a Top Artificial Intelligence (AI) Stock for 2025?
[ Thu, Jan 02nd 2025 ]: MSN
Elon Musk Weighs In on Weight-Loss Drug Stocks. Is LLY or NVO a Better Buy?
[ Tue, Dec 31st 2024 ]: MSN
Why Is Geron Corporation (GERN) Among the Best Biotech Penny Stocks to Invest in Now?
[ Thu, Dec 12th 2024 ]: MSN
[ Thu, Dec 12th 2024 ]: Seeking Alpha
Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable
[ Wed, Dec 11th 2024 ]: Seeking Alpha
[ Tue, Dec 10th 2024 ]: Seeking Alpha
Payoneer Global: The Young Company Is A Strong Candidate For A Growth Portfolio
[ Mon, Dec 09th 2024 ]: Yahoo Finance
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock
[ Wed, Dec 04th 2024 ]: Thomas Matters
[ Wed, Dec 04th 2024 ]: Thomas Matters
[ Mon, Dec 02nd 2024 ]: Thomas Matters